Suppr超能文献

基于RTOG方案的前列腺癌淋巴结放疗后PET/CT上的淋巴结复发模式

Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer.

作者信息

Liskamp C P, Donswijk M L, van der Poel H G, Schaake E E, Vogel W V

机构信息

Department of Radiation Oncology, NKI-AVL, Amsterdam, The Netherlands.

Department of Nuclear Medicine, NKI-AVL, Amsterdam, The Netherlands.

出版信息

Clin Transl Radiat Oncol. 2020 Feb 26;22:9-14. doi: 10.1016/j.ctro.2020.02.006. eCollection 2020 May.

Abstract

PURPOSE

Biochemical failure after external beam radiotherapy (RT) for node-positive prostate cancer (PC) frequently involves nodal recurrences, in most cases out of field. This raises the question if current RTOG-based elective nodal fields can still be considered optimal. Modern diagnostic tools like PSMA PET/CT and choline PET/CT can visualize nodal recurrences with unprecedented accuracy. We evaluated recurrence patterns on PET/CT after RT for PC, with the aim to explore options for improved nodal target definition.

METHODS AND MATERIALS

Data of all patients treated with curative intent EBRT for PC in NKI-AVL from 2008 to 2018 were retrospectively reviewed. EBRT comprised 70 Gy to the prostate or 66-70 Gy to the prostate bed, 60 Gy to involved nodes, and 52,5-56 Gy (46 Gy EQD2) to RTOG-based elective nodal fields, in 35 fractions. Locations of recurrences on PET/CT were noted, and nodal locations were correlated with the applied EBRT fields.

RESULTS

42 patients received PSMA (28) or choline (14) PET/CT at biochemical recurrence. 35 patients (83%) had a positive scan. At their first positive scan 17 patients had nodal metastasis, in some cases together with a local recurrence or distant disease. In-field nodal recurrences were uncommon (n = 3). Out-field nodal recurrences occurred more frequently (n = 14), with the majority (n = 12) just above the elective nodal field. These nodes were the single area of detectable failure in 6 patients (14%).

CONCLUSIONS

Current RT with RTOG-based nodal fields for PC provides good in-field tumour control, but frequent out-field nodal recurrences suggest missed microscopic locations. Expanding elective fields to include the aorta bifurcation may prolong recurrence-free survival. Future research must address whether the potential benefits of this strategy outbalance additional toxicity.

摘要

目的

对于淋巴结阳性前列腺癌(PC),外照射放疗(RT)后的生化失败通常涉及淋巴结复发,在大多数情况下是野外复发。这就提出了一个问题,即目前基于美国放射肿瘤学组(RTOG)的选择性淋巴结照射野是否仍可被视为最佳方案。像前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)和胆碱PET/CT这样的现代诊断工具能够以前所未有的准确性显示淋巴结复发情况。我们评估了PC放疗后PET/CT上的复发模式,旨在探索改进淋巴结靶区定义的方案。

方法和材料

回顾性分析了2008年至2018年在荷兰癌症研究所 - 阿姆斯特丹自由大学医学中心(NKI - AVL)接受根治性意图的PC调强适形放疗(EBRT)的所有患者的数据。EBRT包括对前列腺给予70 Gy或对前列腺床给予66 - 70 Gy,对受累淋巴结给予60 Gy,以及对基于RTOG的选择性淋巴结照射野给予52.5 - 56 Gy(等效剂量2为46 Gy),分35次照射。记录PET/CT上复发的位置,并将淋巴结位置与所应用的EBRT照射野相关联。

结果

42例患者在生化复发时接受了PSMA(28例)或胆碱(14例)PET/CT检查。35例患者(83%)扫描结果为阳性。在首次阳性扫描时,17例患者有淋巴结转移,在某些情况下同时伴有局部复发或远处疾病。野外淋巴结复发并不常见(n = 3)。野外淋巴结复发更频繁(n = 14),大多数(n = 12)位于选择性淋巴结照射野上方。这些淋巴结是6例患者(14%)唯一可检测到的失败区域。

结论

目前基于RTOG淋巴结照射野的PC放疗能很好地控制野外肿瘤,但频繁的野外淋巴结复发提示存在遗漏的微小病灶部位。扩大选择性照射野以包括主动脉分叉处可能会延长无复发生存期。未来的研究必须探讨该策略的潜在益处是否超过额外的毒性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f42a/7056599/25ca8e0d0f59/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验